FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3014346486> ?p ?o ?g. }

• W3014346486 endingPage "220" @default.
• W3014346486 startingPage "211" @default.
• W3014346486 abstract "Eribulin methylate (eribulin) improved the overall survival (OS) of HER2-negative advanced breast cancer (HER2−ABC) patients; however, the mechanism underlying the OS improvement has not been clarified. Several reports suggest that eribulin promotes antitumor immunity via tumor micro-environment conditioning. Recently, a maintained baseline lymphocyte count was proposed as predictive marker for eribulin therapy in HER2−ABC patients; however, no associations with the OS have been noted. We retrospectively investigated the neutrophil-to-lymphocyte ratio and absolute lymphocyte count (ALC) in HER2−ABC patients receiving eribulin and assessed the utility of eribulin re-administration for further OS improvement. HER2−ABC patients who received eribulin therapy at Shizuoka Cancer Center between November 2011 and December 2018 were retrospectively analyzed. A total of 144 HER2−ABC (108 estrogen receptor-positive [ER+], 36 ER−) patients were identified, and 32 patients (28 ER+ , 4 ER−) were re-administered with eribulin. In the ER+ subgroup, a multivariate analysis showed that an ALC ≥ 1000/μL and re-administration were significantly associated with the OS (hazard ratio [HR] 0.503; P = 0.034 and HR 0.366; P < 0.0001, respectively), and an ALC ≥ 1000/μL was also identified as the only predictive factor for re-administration (HR 0.329; P = 0.033). In contrast, a multivariate analysis in the ER- subgroup identified no predictive markers. In HER2−ER + ABC patients, ALC was identified as a predictive marker for eribulin therapy, and the re-administration of eribulin is considered a valid therapeutic option for further improvement of the OS." @default.
• W3014346486 created "2020-04-10" @default.
• W3014346486 creator A5008356782 @default.
• W3014346486 creator A5036684310 @default.
• W3014346486 creator A5040428277 @default.
• W3014346486 creator A5087541425 @default.
• W3014346486 date "2020-04-05" @default.
• W3014346486 modified "2023-09-30" @default.
• W3014346486 title "A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience" @default.
• W3014346486 cites W1586470106 @default.
• W3014346486 cites W1841839849 @default.
• W3014346486 cites W1975536376 @default.
• W3014346486 cites W1982906652 @default.
• W3014346486 cites W1983225377 @default.
• W3014346486 cites W2007990687 @default.
• W3014346486 cites W2039609199 @default.
• W3014346486 cites W2061860268 @default.
• W3014346486 cites W2062425552 @default.
• W3014346486 cites W2088574179 @default.
• W3014346486 cites W2095832858 @default.
• W3014346486 cites W2103118255 @default.
• W3014346486 cites W2107408397 @default.
• W3014346486 cites W2118278569 @default.
• W3014346486 cites W2120676861 @default.
• W3014346486 cites W2123105952 @default.
• W3014346486 cites W2127152525 @default.
• W3014346486 cites W2137545466 @default.
• W3014346486 cites W2138941973 @default.
• W3014346486 cites W2139448267 @default.
• W3014346486 cites W2143994426 @default.
• W3014346486 cites W2147583204 @default.
• W3014346486 cites W2148237316 @default.
• W3014346486 cites W2192078226 @default.
• W3014346486 cites W2346198182 @default.
• W3014346486 cites W2560635244 @default.
• W3014346486 cites W2586608125 @default.
• W3014346486 cites W2753016107 @default.
• W3014346486 cites W2789945124 @default.
• W3014346486 cites W2791153774 @default.
• W3014346486 cites W2791284451 @default.
• W3014346486 cites W2799941962 @default.
• W3014346486 cites W2897279146 @default.
• W3014346486 cites W2925781938 @default.
• W3014346486 doi "https://doi.org/10.1007/s10549-020-05626-1" @default.
• W3014346486 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32249370" @default.
• W3014346486 hasPublicationYear "2020" @default.
• W3014346486 type Work @default.
• W3014346486 sameAs 3014346486 @default.
• W3014346486 citedByCount "19" @default.
• W3014346486 countsByYear W30143464862020 @default.
• W3014346486 countsByYear W30143464862021 @default.
• W3014346486 countsByYear W30143464862022 @default.
• W3014346486 countsByYear W30143464862023 @default.
• W3014346486 crossrefType "journal-article" @default.
• W3014346486 hasAuthorship W3014346486A5008356782 @default.
• W3014346486 hasAuthorship W3014346486A5036684310 @default.
• W3014346486 hasAuthorship W3014346486A5040428277 @default.
• W3014346486 hasAuthorship W3014346486A5087541425 @default.
• W3014346486 hasBestOaLocation W30143464862 @default.
• W3014346486 hasConcept C121608353 @default.
• W3014346486 hasConcept C126322002 @default.
• W3014346486 hasConcept C143998085 @default.
• W3014346486 hasConcept C207103383 @default.
• W3014346486 hasConcept C2775930923 @default.
• W3014346486 hasConcept C2776387010 @default.
• W3014346486 hasConcept C2779786085 @default.
• W3014346486 hasConcept C44249647 @default.
• W3014346486 hasConcept C530470458 @default.
• W3014346486 hasConcept C71924100 @default.
• W3014346486 hasConcept C90924648 @default.
• W3014346486 hasConceptScore W3014346486C121608353 @default.
• W3014346486 hasConceptScore W3014346486C126322002 @default.
• W3014346486 hasConceptScore W3014346486C143998085 @default.
• W3014346486 hasConceptScore W3014346486C207103383 @default.
• W3014346486 hasConceptScore W3014346486C2775930923 @default.
• W3014346486 hasConceptScore W3014346486C2776387010 @default.
• W3014346486 hasConceptScore W3014346486C2779786085 @default.
• W3014346486 hasConceptScore W3014346486C44249647 @default.
• W3014346486 hasConceptScore W3014346486C530470458 @default.
• W3014346486 hasConceptScore W3014346486C71924100 @default.
• W3014346486 hasConceptScore W3014346486C90924648 @default.
• W3014346486 hasIssue "1" @default.
• W3014346486 hasLocation W30143464861 @default.
• W3014346486 hasLocation W30143464862 @default.
• W3014346486 hasOpenAccess W3014346486 @default.
• W3014346486 hasPrimaryLocation W30143464861 @default.
• W3014346486 hasRelatedWork W2102044848 @default.
• W3014346486 hasRelatedWork W2117882776 @default.
• W3014346486 hasRelatedWork W2401868633 @default.
• W3014346486 hasRelatedWork W2588964444 @default.
• W3014346486 hasRelatedWork W2622612196 @default.
• W3014346486 hasRelatedWork W2773744777 @default.
• W3014346486 hasRelatedWork W2898246557 @default.
• W3014346486 hasRelatedWork W3015618437 @default.
• W3014346486 hasRelatedWork W3023019229 @default.
• W3014346486 hasRelatedWork W3091951536 @default.
• W3014346486 hasVolume "181" @default.
• W3014346486 isParatext "false" @default.

• next